An endothelial growth factor receptor compound mutation of T790M substitution with exon 19 deletion in a previously untreated patient: a case report

BACKGROUND: Endothelial growth factor receptor (EGFR) mutations are an essential driver of personalized therapy for patients with lung cancer and are detected in approximately 15% of Caucasian and 50% of Asian patients. EGFR tyrosine kinase inhibitors have been developed and used for this set of pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Falla-Martinez, Juan C., Espinosa, Daniela, Baena, Juan C., Rodriguez, Lisa X., Sua, Luz F., Zambrano, Angela R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518648/
https://www.ncbi.nlm.nih.gov/pubmed/31088573
http://dx.doi.org/10.1186/s13256-019-2075-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518648/
https://www.ncbi.nlm.nih.gov/pubmed/31088573
http://dx.doi.org/10.1186/s13256-019-2075-y

Ejemplares similares